Summary
This article presents findings on the efficacy and safety of a shift from alendronate (ALN) to denosumab (DMAb) in a subset of women from the 1-year Study of Transitioning from Alendronate to Denosumab [STAND; NCT00377819] trial who transitioned to DMAb after 5 or more years of continuous ALN therapy.
- Diabetes & Endocrinology Clinical Trials
- Metabolic Bone Disease
- Menopause
- © 2011 MD Conference Express
Tools
Transitioning to Denosumab from Continuous Alendronate Therapy Further Improves BMD in Postmenopausal Women with Osteoporosis
Permalink:
Table of contents
Cited By...
- No citing articles found.